Abstract 1653P
Background
The presence of minimal intra-pancreatic fat deposition (IPFD) in the healthy human pancreas has been demonstrated in numerous studies. But excess IPFD, leads to a wide array of diseases, including but not limited to diabetes, pancreatitis, and pancreatic cancer (PC). Remarkably, PC patients with excessive intra-pancreatic fat accumulation are commonly associated with a poor prognosis compared to those with minimal IPFD. However, the interaction between tumor and IPFD remains elusive. Here, we evaluated the pancreatic fat infiltration in normal people and patients with PC respectively, and explored how intra-pancreatic fat accelerates tumor progression.
Methods
Magnetic resonance imaging (MRI) and clinical biopsy specimens were used to assess the degree of pancreatic fat infiltration in PC patients and healthy control individuals. The KC, KPC, KCO, and AAV8-ADIPOQ-DTA mice were established to demonstrate that IPFD promoted tumor progression. The single-nucleus sequencing of pancreatic fat tissue and proteomic of PC cell lines were performed to identify the mechanism of interaction between cancer cells and adipocytes.
Results
We found that patients with PC presented excess intra-pancreatic fat deposition more frequently than control individuals, and the degree of fat infiltration was positively correlated with the tumor size of PC patients. High-fat diet KPC mice or KCO mice showed a higher degree of IPFD, which contributed to tumor growth and low survival rates of mice. Besides, the expression of uncoupling protein 1 (UCP1) was upregulated in PC patients or spontaneous tumor mice compared to normal controls. Constantly, the single-nucleus sequencing of pancreatic fat tissue of PC patients demonstrated the increase in thermogenesis features. Specifically, we revealed that PC cells improved the thermogenesis of intra-pancreatic adipose tissue, which in turn promoted PC cell proliferation.
Conclusions
We demonstrated that excess intra-pancreatic fat infiltration fuels the progression of PC, and selectively eliminating fat in the pancreas inhibits tumor growth. Mechanistically, PC cells promote the browning of adipocytes, and then the activated adipocytes enhance the proliferation and migration of cancer cells in response.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
PUMCH.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1624P - Predictive factors for treatment success of second-line Nal-IRI/5-FU/FA in patients with metastatic pancreatic ductal adenocarcinoma (PDAC) (AIO-PAK-0216)
Presenter: Manfred Lutz
Session: Poster session 22
1626P - A novel endoscopic ultrasound guided extended-release siRNA implant targeting KRASG12D/V in localized pancreatic cancer
Presenter: Anna Varghese
Session: Poster session 22
1629P - Modified-FOLFIRINOX-losartan followed by chemoradiotherapy for locally advanced pancreatic cancer: A phase II study
Presenter: Alshaimaa Alhanafy
Session: Poster session 22
1630P - Phase I/Ib study of SHP2-ERK inhibition in KRASm pancreatic cancer (SHERPA trial) and preclinical identification of potential resistance markers
Presenter: Ashwini Cheryl Kanhailal
Session: Poster session 22
1631P - Phase I study of endoscopic ultrasound (EUS)-guided NBTXR3 delivery activated by radiotherapy (RT) for locally advanced or borderline resectable pancreatic cancer (LAPC or BRPC)
Presenter: Gabriela Fuentes
Session: Poster session 22
1632P - Organoids as tools for functional precision oncology in advanced pancreatic cancer
Presenter: Alice Boileve
Session: Poster session 22
1633P - Development and clinical validation of news transcriptomic tools for predicting the response to individual drug of the mfolfirinox regimen in patients with pancreatic ductal adenocarcinoma
Presenter: Nicolas Fraunhoffer
Session: Poster session 22